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Several hereditary risk factors for venous throm-
boembolism (VTE) have been identified [1]. The 
polymorphic variants of genes encoding coagulation 
factors have been investigated as risk factors for ve-
nous thrombosis [2]. Among the inherited clotting ab-
normalities, factor V Leiden (FVL) is the most common 
cause for venous thrombosis. It is known that factor VII 
(FVII) plays an important role in the extrinsic pathway 
of blood coagulation. Its coagulant activity is identified 
as a potential risk factor for venous or arterial throm-
bosis. Several studies have provided the evidence for 
associations between some common polymorphisms 
of FVII gene and FVII blood levels [3–8]. However, other 
authors have not supported this observation [9].
Three common polymorphisms of the promoter 
region in FVII gene locus; a decanucleotide insertion 
at position -323 (-323ins10-bp), a G to T substitution 
at position -401 (-401GT), and a G to A substitution 
at position -402 (-402GA) have been described and 
reported to be associated with FVII blood levels. The 
-323ins10-bp has been extensively studies in rela-
tion to FVII plasma level (3–6, 9). It is proposed that 
-323ins10bp polymorphism may influence the rate of 
transcription of FVII gene. The -323ins10bp is function-
ally relevant; the rare insertion allele of 10-bp reduces 
the promoter activity, as compared with the common 
allele [10]. This insertion allele is related to low blood 
levels of FVII. According to van’t Hooft et al. [4] study, 
-401GT polymorphism is strong linkage disequilibrium 
with the -323ins10-bp polymorphism.
The -401 T allele was associated with significantly 
lower plasma levels of FVII than the common -401 G allele, 
but the rare -402 A allele was associated with significantly 
higher FVII levels than the common -402 G allele.
On the other hand, there has been controversy 
whether the genetic variations in blood FVII levels influ-
ence the development of VTE [8, 11, 12]. High blood 
levels of FVII may be related to hypercoagulable state 
and certain mutations in FVII gene locus contribute to 
the variability in plasma FVII activity. Several studies have 
failed to find any association of FVII gene polymorphisms 
and venous thrombosis, but not arterial thrombosis [7, 8, 
11–13]. A few reports have suggested that those alleles 
associated with low levels of FVII could play a protective 
role against myocardial infarction [5, 6]. Other studies, 
however, failed to detect such as influence [14, 15].
Cancer patients have an increased risk of VTE. 
Recently we have demonstrated the significant as-
sociation between FVL and the risk of VTE in patients 
with cancer [16, 17]. Whether the polymorphism of FVII 
gene is related to an increased risk of VTE in cancer is 
still an open question. There are only a few published 
studies about the effect of FVII gene polymorphisms on 
the risk of idiopathic venous thrombosis [7, 8, 11–13]. 
The published studies have not included in cases with 
secondary VTE due to acquired risk factors including 
malignancy. Koster et al. [11] reported the first study 
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that examined the risk of venous thrombosis in relation 
to Msp1 polymorphism of FVII gene. The polymor-
phism was not associated with the risk of deep venous 
thrombosis (DVT). Besides, no significant association 
of FVII plasma level with DVT was found.
The thrombotic role of several polymorphisms of 
genes encoding haemostatic factors has been inves-
tigated in cancer patients [16, 17]. Although FVL is an 
important risk factor for venous thrombosis in cancer, 
the findings are controversial. If the FVII plays a role as 
a risk factor for VTE, it can be important to investigate 
the association between its functional polymorphism 
and venous thrombosis in cancer patients. In light of 
the postulation, we have evaluated the possible cor-
relation of promoter region polymorphisms of FVII gene 
with risk of VTE in cancer patients.
MATERIALS AND METHODS
The study population has been described previously 
[16, 17]. Briefly, two groups of cancer patients were 
enrolled in the study. Group I consisted of 60 cancer 
patients with VTE (one patient had thrombosis of the 
axillary and subclavian vein; two had pulmonary embo-
lism without DVT; other patients had DVT of the lower 
extremity). Tumor location in this group was as follows: 
breast (n = 16), lung (n = 17), larynx (n = 2), brain (n = 2), 
digestive system (n = 11), genitourinary system (n = 3), 
extremities sarcoma (n = 4), other (n = 5). Group 2 was 
composed of 130 cancer patients with tumors of breast 
(n = 76), lung (n = 24), digestive tract (n = 6), larynx (n = 
3), brain (n = 5), sarcoma (n = 5), genitourinary system 
(n = 3), others (n = 8), who had no history of thrombo-
embolic disease during the cancer therapy or follow-up 
period. In general, tumor stages according to TNM clas-
sification were similar in both groups. For example, the 
distribution of tumor stage for breast cancer in groups 
1 and 2 was as follows: early stage (stage I/II) in 8 pa-
tients and advanced stage in 8 patients in group 1; early 
stage in 39 and advanced stage in 37 patients in group 
2. All patients with breast cancer in two groups had in-
vasive tumors. The lung cancer patients in both groups 
had advanced stage of disease. Five of 11 patients with 
digestive system cancer in group 1 had metastasis. 
Three of 6 patients with digestive system cancer in 
group 2 had stage 4 cancer. Before the collection of 
peripheral blood, all patients gave informed consent to 
participate in this study. Ethical committee approval was 
obtained for molecular studies on thrombosis.
DNA was isolated from peripheral blood lympho-
cytes by the standard phenol-chloroform method. 
Genomic DNA was amplified by polymerase chain 
reaction (PCR). Genotyping was performed by single-
strand conformation polymorphism (SSCP) analysis 
and sequencing of all identified patterns. The primer 
design was based on the sequence of the promoter 
region of FVII gene. The 323ins10-bp, -401GT, 402GA 
polymorphisms in the promoter region of FVII gene 
were amplified [3, 4, 10, 18]. The PCR reaction started 
with 5 min at 95 °C and was continued by 34 cycles of 
94 °C/1 min, 60 °C/1 min, 72 °C/1 min, and final exten-
sion of 10 min at 72 °C (Biometra, Germany). The PCR 
samples were run on 2% agarose gel.
SSCP was carried out using the following primers: F 
5’-GGC CTG GTC TGG AGG CTC TCT TC-3’; R 5’-CGC 
TGG CAA CAA AAC CGT CCG CTC-3’ [15, 18]. The 
amplified DNA fragment was 214 bp for SSCP. The PCR 
products were denatured at 99 °C for 7 min and then 
the resulting single-stranded DNA was loaded on 8% 
polyacrylamide gel. Electrophoresis was performed 
with a sequencing apparatus at 130 V of constant 
power at 4 °C for 10 to 12 h depending on the fragment 
size. After electrophoresis, gel was silver stained and 
was visualized under ultraviolet light.
A 315-bp DNA fragment was amplified for DNA 
sequencing using the following specific primers: 
F 5’-GTA AGA TGT GGA CCG CTG GA-3’ and R 5’-ACA 
AAA CCG TCC GCT CTG-3’. PCR was carried out after 
choosing the different band profiles of SSCP analysis.
Prior to sequencing, the samples were purified 
by using a PCR purification kit (Agencourt, Ampure, 
Beckman Coulter, USA) and then the DNA sequence 
analysis was performed using an automatic sequencer 
[18] (Beckman Coulter CEQ 8000, Beckman Coulter, 
Fullerton, California, USA).
In addition to these polymorphisms, FVL was 
determined in all cases [17]. The frequencies of the 
alleles and genotypes associated with each of three 
polymorphisms of FVII gene and FVL between two 
groups were compared by chi-square or two-sided 
Fisher exact test, as appropriate. Haplotype analysis 
for FVII gene was also carried out and the distribution 
of the haplotypes between two groups was compared. 
Odds ratios (OR) were calculated as estimate of 
relative risk, together with 95% confidence intervals 
(95% CI). All the statistical analyses were also per-
formed after cases with FVL were excluded from the 
study. All observed genotype and allele frequencies 
were tested for compliance with Hardy-Weinberg 
equilibrium. Statistical significance was determined 
as p < 0.05. The statistical analysis was made using 
SPSS software (SPSS Inc., Chicago, IL).
RESULTS
In all groups, the genotype distributions and allele 
frequencies were in Hardy-Weinberg equilibrium. The 
genotypes and allelic frequencies of the -323ins 10-bp, 
-401GT, -402GA polymorphisms among the patients 
with and without VTE were summarized in Table 1. The 
frequencies of these polymorphisms were not signifi-
cantly different in the two groups (p > 0.05). Interes-
tingly, two mutations in the promoter region of FVII gene 
(-401GT and -323ins10-bp) occurred simultaneously.
As shown in Table 2, there was no significant dif-
ference in the distribution of six haplotypes between 
group 1 and 2 patients.
For FVL, we observed the mutation in 25% (15 of 60) 
and 1.54% (2 of 130) of patients in group 1 and group 2, 
respectively. This difference between the two groups 
was found to be statistically significant (p < 0.0001).
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Table 1. Distribution of three common polymorphisms, -323 ins 10-bp, 
-401 G/T, and -402 G/A in the promoter region of FVII gene in cancer 
patients with (group 1) and without venous thrombosis (group 2)
FVII
Polymorphisms
Group 1
(n = 60)
Group 2
(n = 130) p value
-323 ins10-bp
w/w 33 (55%) 80 (61.5%)
ins/w 25 (41.6%) 45 (34.6%) 0.9
ins/ins 2 (3.3%) 5 (3.8%)
w allele 0.76 0.79
ins allele 0.24 0.21
-401 G/T
GG 33 (55%) 80 (61.5%)
GT 25 (41.6%) 45 (34.6%) 0.9
TT 2 (3.3%) 5 (3.8%)
G allele 0.76 0.79
T allele 0.24 0.21
-402 G/A
GG 48 (80%) 89 (68.5%)
GA 11 (18.3%) 34 (26.2%) 0.7
AA 1 (1.6%) 7 (5.4%)
G allele 0.89 0.815
A allele 0.11 0.185.
In Tables 1, 3: Ins — insertion; w — wild type.
Table 2. Distribution of haplotype of FVII in patients with (group 1) and 
without thrombosis (group 2)
Haplo type Group 1 (n = 60)
Group 2 
(n = 130) OR (CI) p value
I 25 (41.6%) 46 (35.4%) 1
II 1 (1.6%) 7 (5.4%) 0.3 (0.03–2.3) 0.6
III 7 (11.6%) 27 (20.8%) 0.5 (0.2–1.3) 0.2
IV 21 (35%) 38 (29.2%) 1 (0.5–2) 0.9
V 4 (6.6%) 7 (5.4%) 1 (0.3–3.9) 0.8
VI 2 (3.3%) 5 (3.8%) 0.7 (0.1–4.1) 0.9
I: -402GG/-401GG/-323w/w; II: -402AA/-401GG/-323w/w;
III: -402GA/-401GG/-323w/w; IV: -402GG/-401GT/-323ins/w;
V: -402GA/-401GT/-323ins/w; VI: -402GG/-401TT/-323ins/ins
Notes: OR — odds ratio; CI — 95% confidence interval.
We next calculated the prevalence of the -323ins10-
bp, -401GT, -402GA polymorphisms in two groups pa-
tients after excluding FVL mutation positive patients. 
No difference was also detected in the distribution of 
-323ins10-bp,-401GT, -402GA genotypes in cancer 
patients with VTE versus those without VTE (p > 0.05). 
Their allelic frequencies between two groups were 
also found to be statistically insignificant (Table 3). In 
addition, the haplotype frequencies showed a similar 
distribution among cancer patients with and without 
VTE (p > 0.05) (data not shown).
Table 3. Prevalence of -323 ins 10-bp, -401 G/T, and -402 G/A polymorphisms 
of FVII gene in cancer patients with (group 1) and without venous thrombosis 
(group 2) after exclusion of patients carriers of FVL
FVII
Polymorphisms
Group 1
(n = 45)
Group 2
(n = 128) p value
-323 ins10-bp
w/w 21 (46.6%) 79 (61.7%)
ins/w 22 (48.8%) 44 (34.4%) 0.8
ins/ins 2 (4.4%) 5 (3.9%)
w allele 0.71 0.79
ins allele 0.29 0.21
-401 G/T
GG 21 (46.6%) 79 (61.7%)
GT 22 (48.8%) 44 (34.4%) 0.8
TT 2 (4.4%) 5 (3.9%)
G allele 0.71 0.79
T allele 0.29 0.21
-402 G/A
GG 37 (82.2%) 87 (67.9%)
GA 7 (15.5%) 34 (26.5%) 0.8
AA 1 (2.2%) 7 (5.5%)
G allele 0.9 0.813
A allele 0.1 0.187
DISCUSSION
Thrombosis is one of the most common compli-
cations in patients with malignant disease [19, 20]. 
The pathogenesis of haemostatic disorders in cancer 
reflects the interaction of different mechanisms inclu-
ding cancer-related factors such as venous stasis, the 
effects of treatment, especially chemotherapy and 
patient-specific factors such as thrombophilic status 
of cancer patients, acquired or congenital disorders 
of hemostasis. Several molecules of the coagulation 
and fibrinolytic systems are activated in cancer. Cancer 
cells can also produce TF and cancer procoagulants 
which activated the coagulation system [20].
FVII plays a key role in the extrinsic pathway of blood 
coagulation. High plasma FVII levels can be associated 
with venous or arterial thrombosis. The polymorphisms 
in the FVII gene may contribute to the variations in 
plasma levels of FVII. Therefore, it may be postulated 
that these polymorphisms precipitate venous thrombo-
sis. Previous studies demonstrated that the rare alleles 
of the polymorphisms at positions -401 and -402 were 
related to marked changes in the rate of FVII gene 
transcription [4]. The -323ins10-bp polymorphism was 
directly related to the decrease in transcription [10].
The common polymorphisms in the promoter 
region of FVII gene may influence FVII blood levels 
because they may modulate its transcription [4, 9, 10]. 
Corral et al. [21] showed that carriers of the -323ins 
allele had an increased risk for intracranial hemorrhage 
and they found statistically significant differences in 
the prevalence of FVII -323ins10-bp polymorphism 
between patients and controls.
On the other hand, some studies have investigated 
the role of common polymorphisms influencing the 
FVII plasma levels in thrombotic disorders with con-
flicting results. There have been a few studies which 
evaluate the relationship between idiopathic VTE and 
some common polymorphisms of FVII gene [7, 8, 
11–13]. The studies failed to show an association be-
tween the risk of VTE and the polymorphisms known 
to modulate blood FVII levels. Corral and colleagues 
[12] demonstrated no significant association between 
-323ins10-bp polymorphism and the risk of DVT. More 
recently, Folsom et al. [8] have shown that FVII 402GA 
polymorphism is not associated with VTE occurrence. 
It should be emphasized that the published studies 
have not included in cases with secondary VTE due to 
acquired risk factors including malignancy.
To our knowledge, the present study is the first to ad-
dress the potential association between venous throm-
bosis and the common promoter region polymorphisms 
of FVII gene in cancer patients. Our studies showed that 
the promoter region polymorphisms were not strong 
determinants of venous thrombosis in cancer patients.
According to some previous studies, the -401GT 
polymorphism is the linkage disequilibrium with 
-323ins10-bp polymorphism [3, 4, 10]. In agreement 
with the reports, 401GT polymorphism showed com-
plete allelic association with -323ins10-bp polymor-
phism in our series.
18 Experimental Oncology 32, 15–18, 2010 (March)
FVL is a well-established risk factor in the deve-
lopment of DVT [1, 2]. It is the most common genetic 
defect causing thrombosis among Caucasians. In ge-
neral, the risk of venous thrombosis is 5–10-fold higher 
in cases carrying heterozygous and 50–80-fold higher in 
cases with homozygous for FVL. However, the role of he-
reditary thrombophilia in cancer patients with VTE is still 
unclear [16, 17, 19]. Some authors have been evaluated 
the role of FVL mutation on the thrombosis risk in malig-
nancy [17]. Previously, we demonstrated a significant 
association between FVL and venous thrombosis risk 
in cancer patients [16, 17]. In this study, the frequency 
FVL in cancer patients with VTE was significantly higher 
than in those without VTE. The high prevalence of FVL in 
cancer patients with thrombosis can be associated with 
the high frequency among healthy Turkish population 
[22]. After exclusion of patient carriers of FVL, the rela-
tionship between the FVII gene polymorphisms and VTE 
was evaluated in our series. When the statistical analysis 
was also performed, the same insignificant results were 
observed. Accordingly it can be suggested that the 
screening for FVII polymorphisms does not contribute to 
a meaningful diagnostic investigation of thrombophilia in 
cancer patients with VTE.
Although the present study is the first to evalu-
ate the association between venous thrombosis risk 
and the promoter region polymorphisms of FVII gene 
among cancer patients, there are a few limitations. 
Firstly, we have not determined FVII plasma levels in 
our cases. Other limitation is its small size. Another 
limitation of our study is that patients with different 
types of cancer were enrolled. Therefore the interpre-
tation of the results can be complicated.
In conclusion, our study has suggested that three 
promoter polymorphisms of FVII gene; 323ins10-bp, 
-401GT, and -402GA are not contributing variants to VTE 
occurrence in cancer patients. FVL is the significant risk 
factor for the development of VTE but there is no additive 
effect of these polymorphisms of FVII gene in cancer. 
However, further larger studies including different ethnic 
population are required to better clarify the association 
of FVII polymorphisms with the thrombosis risk.
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